KalVista Pharmaceuticals (KALV) Total Non-Current Liabilities (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Total Non-Current Liabilities of $136.3 million in Q3 2025, up 23.71% quarter-over-quarter from $110.2 million in Q2 2025, and up 2633.36% year-over-year from $5.0 million in Q3 2024.
KalVista Pharmaceuticals' Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $136.3 million for Q3 2025.
- In Q3 2025, Total Non-Current Liabilities rose 2633.36% year-over-year to $136.3 million; the TTM figure through Jul 2025 stood at $136.3 million (up 2633.36% YoY), while the FY2025 annual figure was $110.2 million, up 1732.29% from the prior year.
- Total Non-Current Liabilities came in at $136.3 million for Q3 2025 at KalVista Pharmaceuticals, up from $110.2 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $136.3 million in Q3 2025 to a low of $1.1 million in Q1 2021.
- A 5-year average of $19.8 million and a median of $6.9 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Across the five-year window, Total Non-Current Liabilities sank 67.22% in 2021 and surged 2633.36% in 2025, its largest moves.
- KalVista Pharmaceuticals' Total Non-Current Liabilities stood at $6.2 million in 2021, then rose by 23.79% to $7.7 million in 2022, then retreated by 15.04% to $6.5 million in 2023, then jumped by 366.71% to $30.6 million in 2024, then jumped by 346.27% to $136.3 million in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $136.3 million, $110.2 million, and $30.6 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 136.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 136.34 Mn |
| Apr 30, 2025 | 110.21 Mn |
| Dec 31, 2024 | 30.55 Mn |
| Oct 31, 2024 | 4.68 Mn |
| Jul 31, 2024 | 4.99 Mn |
| Apr 30, 2024 | 6.02 Mn |
| Jan 31, 2024 | 6.26 Mn |
| Oct 31, 2023 | 6.55 Mn |
| Jul 31, 2023 | 6.87 Mn |
| Apr 30, 2023 | 7.15 Mn |
| Jan 31, 2023 | 7.42 Mn |
| Oct 31, 2022 | 7.71 Mn |
| Jul 31, 2022 | 8.01 Mn |
| Apr 30, 2022 | 7.21 Mn |
| Jan 31, 2022 | 7.47 Mn |
| Oct 31, 2021 | 6.22 Mn |
| Jul 31, 2021 | 6.47 Mn |
| Apr 30, 2021 | 5.05 Mn |
| Jan 31, 2021 | 1.12 Mn |
| Oct 31, 2020 | 932,000.00 |
| Jul 31, 2020 | 1.01 Mn |
| Apr 30, 2020 | 1.06 Mn |
| Jan 31, 2020 | 3.43 Mn |
| Oct 31, 2019 | 3.81 Mn |
| Jul 31, 2019 | 4.05 Mn |
| Apr 30, 2019 | 3.34 Mn |
| Jan 31, 2019 | 3.67 Mn |
| Oct 31, 2018 | 4.67 Mn |
| Jul 31, 2018 | 8.47 Mn |
| Apr 30, 2018 | 10.92 Mn |
| Jan 31, 2018 | 14.01 Mn |
| Oct 31, 2017 | 149,000.00 |
| Jul 31, 2017 | 213,000.00 |
| Mar 31, 2016 | 6.60 Mn |
| Dec 31, 2015 | 7.48 Mn |
| Mar 31, 2015 | 14.84 Mn |
| Dec 31, 2014 | 9.77 Mn |